홈
마켓
차트 & 아이디어
Algo
뉴스
Store
브로커
다운로드
경제 달력
트레이딩 시그널
웹터미널
검색
/
타입: @user, $symbol
검색
로그인
계정을 생성하십시오
English
Русский
中文
Español
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
GLMD
#4054
Galmed Pharmaceuticals Ltd.
0.6
1
-7.58%
부문:
베이스:
수익 통화:
일일 변동 비율
년간 변동
일일 변동
-7.58%
월간 변동
-28.24%
6달 변화
-56.74%
년간 변동율
-72.27%
이전 종가
0.6
6
Open
0.6
1
Bid
Ask
Low
0.6
1
High
0.6
1
양
2
마켓
주식
헬스케어
GLMD
Open full chart
Financials
Overview
성명
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
1.65 M
2.35 M
Valuation ratios
Enterprise value
577.63 K
—
Price to earnings ratio
0.39
—
Price to sales ratio
—
—
Price to cash flow ratio
0.5
—
Price to book ratio
0.18
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
-0.19
-0.85
Return on equity %
-0.21
-1.02
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
7.42
23.13
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
0.05
0.16
Long term debt to total equity ratio
0.05
0.19
Per share metrics
Operating cash flow per share
-3.71
-105.21
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
12.78
411.18
Net current asset value per share
17.32
443.93
Tangible book value per share
17.54
396.94
Working capital per share
14.99
364.51
Book value per share
17.54
396.94
뉴스
Galmed Pharmaceuticals schedules special shareholder meeting for March 4
Galmed Pharmaceuticals receives Nasdaq minimum bid price notice
Galmed to present data on Aramchol’s potential in liver cancer
Galmed stock rises after patent grant for MASH combo therapy
Galmed receives patent for combination therapy in South Korea
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook
Galmed reports $19.2 million cash position, advances Aramchol programs
Galmed stock soars after promising cancer treatment research results
Galmed reports 3-drug combo enhances cancer treatment efficacy
Galmed Pharmaceuticals schedules annual general meeting for October 28
Galmed to invest up to $10M in digital assets as part of new strategy
Galmed plans to invest up to $10 million in digital assets